ESMO Virtual 2020: Treatment-free survival after immunotherapy vs. targeted therapy for advanced kidney cancer

Over the past 2 years, the use of combination therapies for the first-line treatment of metastatic renal cell carcinoma (RCC) has become the standard of care for these patients. The first combination was nivolumab plus ipilimumab, which demonstrated a survival benefit over sunitinib in patients with intermediate and poor risk metastatic RCC (CheckMate-214). Shortly after, […]

read more

Rational approaches to treatment duration with immunotherapy for kidney cancer

A recent review of the use of immune checkpoint inhibitors for the treatment of metastatic renal cell carcinoma (RCC) was published in European Urology Focus this month. The use of immune checkpoint inhibitors has revolutionised the treatment of metastatic RCC over recent years. However, the appropriate duration of treatment with immune checkpoint inhibitors, such as […]

read more

Extended duration of active surveillance of small renal masses

A recent study published in the Journal of Urology evaluated the outcomes of 103 patients with small renal masses (<6 cm) who were on active surveillance. The patients were followed for a median of 55.5 months, and in that time only 1% died of metastatic renal cell carcinoma (RCC). Of the 103 patients, 51.5% survived […]

read more

ESMO 2018: Longer treatment-free survival for ipilimumab/nivolumab combination versus sunitinib

Analysis of the phase 3 CheckMate-214 study has shown that the ipilimumab + nivolumab combination resulted in a significantly longer treatment-free survival period for patients with previously untreated advanced or metastatic renal cell carcinoma (RCC) than patients who were treated with the standard of care, sunitinib. Data from the CheckMate-214 study were presented at the […]

read more
Showing all 4 results